Description
Drug Discovery Targeting Drug-Resistant Bacteria
Coordinators: Kesharwani Prashant, Chopra Sidharth, Dasgupta Arunava
Language: English
Subjects for Drug Discovery Targeting Drug-Resistant Bacteria:
Keywords
anthrax; antibacterial; antibacterial drug targets; antibacterial pipeline; antibacterial resistance; antibacterials; antibiotic discovery; antibiotic resistance; antibiotic target discovery; antibiotics; antimicrobial; antimicrobial resistance; antiviral; bacteremia; bacteria; biofilm; biosensors; biosynthetic gene clusters; biotherapeutic; biothreat pathogens; carbapenems; central dogma; chemotherapy; clinical trials; colistin; determinants; drug discovery; drug resistance; drug susceptibility testing; drug-discovery; drug-resistance; drugs; Ebola; efflux pump; Gram-negative; Gram-positive infections; inhibitors; lysin; magic bullet; mechanisms of antibacterial drug action; medical science; MRSA; multidrug resistance; multidrug-resistant bacteria; Mycobacterium abscessus; Mycobacterium avium; Mycobacterium tuberculosis; nanoparticles; natural products; nature-derived antibiotics; nontuberculous mycobacteria; omics; Pews Trust; quorum sensing; resistance; semisynthetic antibiotics; Staphylococcus aureus; stem cells; synthetic antibacterial agents; target-based technologies; therapeutics; tuberculosis
432 p. · 19x23.3 cm · Paperback
Description
/li>Contents
/li>Readership
/li>Biography
/li>Comment
/li>
Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.
Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.
1. What are drugs and why are they required?2. Drugs against gram-negative bacteria3. Drugs targeting gram-positive bacteria4. Drug repurposing against bacteria5. Drugs against M. tuberculosis6. Drugs against TB and Bioweapons7. New approaches to drug discovery: Peptides/quorum sensing/virulence8. New strategies and targets for antibacterial discovery9. Targeting efflux pumps for AMR10. Discovering antibiotics from Phages11. Drugs against non-tuberculous mycobacteria
Dr. Prashant Kesharwani is working as an assistant professor of pharmaceutics at the School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 20 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also a receipt of several internationally acclaimed awards such as the most prestigious “Ramanujan Fellowship Award from the Science and Engineering Research Board, Government of India. He actively participates in outreach and scientific dissemination for the service of the wider community.
Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens.
Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.
- Written by scientists with extensive industrial experience in drug discovery
- Provides a balanced view of the field, including its challenges and future directions
- Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war